Medesis Pharma SA
PAR:ALMDP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Medesis Pharma SA
Operating Expenses
Medesis Pharma SA
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Medesis Pharma SA
PAR:ALMDP
|
Operating Expenses
-€3.3m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Technip Energies NV
PAR:TE
|
Operating Expenses
-€503.5m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vallourec SA
PAR:VK
|
Operating Expenses
-€507m
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Fiducial Real Estate SA
PAR:ORIA
|
Operating Expenses
-€45m
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
A
|
Altareit SCA
PAR:AREIT
|
Operating Expenses
-€345.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
|
F
|
Frey SA
PAR:FREY
|
Operating Expenses
-€40.3m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-21%
|
|
Medesis Pharma SA
Glance View
Medesis Pharma SA operates as a clinical development stage biopharmaceutical company. The company is headquartered in Baillargues, Occitanie. The company went IPO on 2021-02-12. The firm is engaged through its drug delivery technology Aonys in the development of orally administered molecule drug candidates to expand their therapeutic usefulness to address unmet medical needs. Its technology is also being used for collaborative research programs focused on oncology (customized cancer treatment) and radiotherapy (protection of healthy tissue). The Company’s two drug candidates for treating people contaminated following a civil or military nuclear accident are Plutonium decorporation and Cesium decorporation.
See Also
What is Medesis Pharma SA's Operating Expenses?
Operating Expenses
-3.3m
EUR
Based on the financial report for Dec 31, 2021, Medesis Pharma SA's Operating Expenses amounts to -3.3m EUR.
What is Medesis Pharma SA's Operating Expenses growth rate?
Operating Expenses CAGR 3Y
-39%
Over the last year, the Operating Expenses growth was -182%. The average annual Operating Expenses growth rates for Medesis Pharma SA have been -39% over the past three years .
